home All News open_in_new Full Article

Enveric Biosciences Successfully Completes Key Manufacturing Milestones in Support of Planned IND and Clinical Trials

Key CMC achievements advance EB-003 on the path to first-in-human trials CAMBRIDGE, Mass. — Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced significant progress in the chemistry, manufacturing, and controls (CMC) development of its lead candidate, EB-003. Important steps […]


today 3 d. ago attach_file Economics

attach_file Economics
attach_file Other
attach_file Science
attach_file Science
attach_file Other
attach_file Other
attach_file Science


ID: 3873787392
Add Watch Country

arrow_drop_down